Description: TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. It develops and commercializes drug products based on its Thin film Freezing (TFF) technology platform. The firm also engages in research, development & drug formulation and initial testing of drug products. The company was founded in 2005 and is headquartered in Toronto, Canada.
Home Page: www.tffpharma.com
TFFP Technical Analysis
1751 River Run
Austin,
TX
76107
United States
Phone:
817 438 6168
Officers
| Name | Title |
|---|---|
| Dr. Harlan F. Weisman | Interim CEO & Vice Chairman |
| Mr. Kirk Allen Coleman | CFO, Treasurer & Sec. |
| Mr. Christopher Cano | COO & VP of Bus. Devel. |
| Dr. Anthony J. Hickey Ph.D. | Chief Scientific Officer |
| Dr. Dale Christensen Ph.D. | Head of Clinical Devel. |
| Mr. Paul F. Manley | Head of Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.515 |
| Price-to-Sales TTM: | 133.4649 |
| IPO Date: | 2019-10-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |